Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1128/aac.02395-21 http://scihub22266oqcxt.onion/10.1128/aac.02395-21 35041508!8923226!35041508     free     free     free Nephropedia Template TP {{tp|p=35041508|t=2022. The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways |pdf=|usr=}} gab.com Text The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways JO: Antimicrob Agents Chemother http://www.kidney.de/pget.php?&tw=1&pmid=35041508 #FOAvip Recently, remdesivir and molnupiravir were approved for treating COVID-19 caused by SARS-CoV-2 infection. However, little is known about the impact of these drugs on other viruses preexisted in COVID-19 patients. Here we report that remdesivir but not molnupiravir induced lytic reactivation of Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV), two major oncogenic herpesviruses. Remdesivir induced mature virion production from latently infected cells. Mechanistic studies showed that remdesivir induced KSHV and EBV reactivation by regulating several intracellular signaling pathways. Twit Text FOAVip The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways 🦆🦆Antimicrob Agents Chemother http://www.kidney.de/pget.php?&tw=1&pmid=35041508 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=35041508 #FOAvip English Wikipedia <ref>{{Cite pmid|35041508}}</ref> The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways #MMPMID35041508 Chen J; Dai L; Kendrick S; Post SR; Qin Z Antimicrob Agents Chemother 2022[Mar]; 66 (3): e0239521 PMID35041508show ga Recently, remdesivir and molnupiravir were approved for treating COVID-19 caused by SARS-CoV-2 infection. However, little is known about the impact of these drugs on other viruses preexisted in COVID-19 patients. Here we report that remdesivir but not molnupiravir induced lytic reactivation of Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV), two major oncogenic herpesviruses. Remdesivir induced mature virion production from latently infected cells. Mechanistic studies showed that remdesivir induced KSHV and EBV reactivation by regulating several intracellular signaling pathways. |*COVID-19 Drug Treatment[MESH] |*Epstein-Barr Virus Infections[MESH] |*Herpesvirus 8, Human[MESH] |Adenosine Monophosphate/analogs & derivatives[MESH] |Alanine/analogs & derivatives[MESH] |Herpesvirus 4, Human/physiology[MESH] |Humans[MESH] |SARS-CoV-2[MESH] |Signal Transduction[MESH] |Virus Activation[MESH]The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus React(epmc).pdf DeepDyve Pubget Overpricing